These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27624471)

  • 1. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
    McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ
    Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.
    Supan C; Mombo-Ngoma G; Dal-Bianco MP; Ospina Salazar CL; Issifou S; Mazuir F; Filali-Ansary A; Biot C; Ter-Minassian D; Ramharter M; Kremsner PG; Lell B
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3165-73. PubMed ID: 22430976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria.
    Adoke Y; Zoleko-Manego R; Ouoba S; Tiono AB; Kaguthi G; Bonzela JE; Duong TT; Nahum A; Bouyou-Akotet M; Ogutu B; Ouedraogo A; Macintyre F; Jessel A; Laurijssens B; Cherkaoui-Rbati MH; Cantalloube C; Marrast AC; Bejuit R; White D; Wells TNC; Wartha F; Leroy D; Kibuuka A; Mombo-Ngoma G; Ouattara D; Mugenya I; Phuc BQ; Bohissou F; Mawili-Mboumba DP; Olewe F; Soulama I; Tinto H;
    Malar J; 2021 May; 20(1):222. PubMed ID: 34011358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I randomized dose-ascending placebo-controlled trials of ferroquine--a candidate anti-malarial drug--in adults with asymptomatic Plasmodium falciparum infection.
    Mombo-Ngoma G; Supan C; Dal-Bianco MP; Missinou MA; Matsiegui PB; Ospina Salazar CL; Issifou S; Ter-Minassian D; Ramharter M; Kombila M; Kremsner PG; Lell B
    Malar J; 2011 Mar; 10():53. PubMed ID: 21362162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border.
    Barends M; Jaidee A; Khaohirun N; Singhasivanon P; Nosten F
    Malar J; 2007 Jun; 6():81. PubMed ID: 17597537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.
    McCarthy JS; Baker M; O'Rourke P; Marquart L; Griffin P; Hooft van Huijsduijnen R; Möhrle JJ
    J Antimicrob Chemother; 2016 Sep; 71(9):2620-7. PubMed ID: 27272721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study.
    Held J; Supan C; Salazar CL; Tinto H; Bonkian LN; Nahum A; Moulero B; Sié A; Coulibaly B; Sirima SB; Siribie M; Otsyula N; Otieno L; Abdallah AM; Kimutai R; Bouyou-Akotet M; Kombila M; Koiwai K; Cantalloube C; Din-Bell C; Djeriou E; Waitumbi J; Mordmüller B; Ter-Minassian D; Lell B; Kremsner PG
    Lancet Infect Dis; 2015 Dec; 15(12):1409-19. PubMed ID: 26342427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
    Watts RE; Odedra A; Marquart L; Webb L; Abd-Rahman AN; Cascales L; Chalon S; Rebelo M; Pava Z; Collins KA; Pasay C; Chen N; Peatey CL; Möhrle JJ; McCarthy JS
    PLoS Med; 2020 Aug; 17(8):e1003203. PubMed ID: 32822347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria.
    Gansane A; Lingani M; Yeka A; Nahum A; Bouyou-Akotet M; Mombo-Ngoma G; Kaguthi G; Barceló C; Laurijssens B; Cantalloube C; Macintyre F; Djeriou E; Jessel A; Bejuit R; Demarest H; Marrast AC; Debe S; Tinto H; Kibuuka A; Nahum D; Mawili-Mboumba DP; Zoleko-Manego R; Mugenya I; Olewe F; Duparc S; Ogutu B
    Malar J; 2023 Jan; 22(1):2. PubMed ID: 36597076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antimalarial ferroquine: from bench to clinic.
    Biot C; Nosten F; Fraisse L; Ter-Minassian D; Khalife J; Dive D
    Parasite; 2011 Aug; 18(3):207-14. PubMed ID: 21894260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum.
    Barber BE; Webster R; Potter AJ; Llewellyn S; Sahai N; Leelasena I; Mathison S; Kuritz K; Flynn J; Chalon S; Marrast AC; Gobeau N; Moehrle JJ
    Int J Antimicrob Agents; 2024 Jul; 64(1):107196. PubMed ID: 38734217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum.
    Kreidenweiss A; Kremsner PG; Dietz K; Mordmüller B
    Am J Trop Med Hyg; 2006 Dec; 75(6):1178-81. PubMed ID: 17172389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.
    McCarthy JS; Marquart L; Sekuloski S; Trenholme K; Elliott S; Griffin P; Rockett R; O'Rourke P; Sloots T; Angulo-Barturen I; Ferrer S; Jiménez-Díaz MB; Martínez MS; Hooft van Huijsduijnen R; Duparc S; Leroy D; Wells TN; Baker M; Möhrle JJ
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3669-75. PubMed ID: 27044554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.
    Krause A; Dingemanse J; Mathis A; Marquart L; Möhrle JJ; McCarthy JS
    Br J Clin Pharmacol; 2016 Aug; 82(2):412-21. PubMed ID: 27062080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
    McCarthy JS; Rückle T; Elliott SL; Ballard E; Collins KA; Marquart L; Griffin P; Chalon S; Möhrle JJ
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with
    Collins KA; Rückle T; Elliott S; Marquart L; Ballard E; Chalon S; Griffin P; Möhrle JJ; McCarthy JS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30858218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated
    Supan C; Mombo-Ngoma G; Kombila M; Ospina Salazar CL; Held J; Lell B; Cantalloube C; Djeriou E; Ogutu B; Waitumbi J; Otsula N; Apollo D; Polhemus ME; Kremsner PG; Walsh DS
    Am J Trop Med Hyg; 2017 Aug; 97(2):514-525. PubMed ID: 28722611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ferroquine against artemisinin-based combination therapy (ACT)-resistant Plasmodium falciparum isolates from Cambodia.
    Mairet-Khedim M; Nardella F; Khim N; Kim S; Kloeung N; Ke S; Kauy C; Eam R; Khean C; Pellet A; Leboulleux D; Leang R; Ringwald P; Barale JC; Leroy D; Menard D; Witkowski B
    J Antimicrob Chemother; 2019 Nov; 74(11):3240-3244. PubMed ID: 31518407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
    McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
    Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.